Related Experiment Video
Updated: Jun 20, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Emerging drugs for small-cell lung cancer
Giulio Metro1, Federico Cappuzzo
1Istituto Clnico Humanitas, Division of Hematology-Oncology, 20089 Rozzano (MI), Italy. federico.cappuzzo@humanitas.it
Expert Opinion on Emerging Drugs
|August 22, 2009
Summary
New chemotherapy and targeted agents show promise for small-cell lung cancer (SCLC), a rapidly progressing tumor. Research focuses on amrubicin, anti-angiogenic strategies, and Bcl-2 inhibitors to improve patient survival.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Background:
- Small-cell lung cancer (SCLC) demonstrates rapid progression with limited chemotherapy impact on survival.
- Medical management of SCLC has seen minimal advancement over 30 years, with platinum-based chemotherapy remaining standard.
- Survival improvements have primarily resulted from innovative radiation strategies.
Purpose of the Study:
- To review promising novel agents for SCLC treatment.
- To discuss emerging chemotherapeutic and targeted agents in clinical evaluation.
- To highlight advancements in understanding SCLC biology driving new drug development.
Main Methods:
- Review of current clinical trials and research on SCLC therapeutics.
- Analysis of novel chemotherapeutic agents, including amrubicin.
- Evaluation of targeted agents such as anti-angiogenic strategies and Bcl-2 inhibitors.
Main Results:
- Amrubicin, a synthetic anthracycline, shows significant activity in SCLC.
- Ongoing Phase III trials are assessing amrubicin in first-line extensive-stage and relapsed SCLC.
- Anti-angiogenic strategies and Bcl-2 inhibitors are promising targeted approaches, tested in combination or as maintenance therapy.
Conclusions:
- Recent biological insights into SCLC are fueling the development of new, active drugs.
- Amrubicin and targeted agents like anti-angiogenics and Bcl-2 inhibitors represent the most promising avenues for improving SCLC outcomes.
- Combination and maintenance therapies involving these novel agents are under active investigation.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...